Letters
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 15 4373
Studies. J. Med. Chem. 2007, 50, 3054–3061. (c) Chen, Y. F.; Lopex-
Sanchez, M.; Savoy, D. N.; Billadieu, D. D.; Dow, G. S.; Kozikowski,
A. P. A series of potent and selective, triazolylphenyl-based histone
deacetylase inhibitors [HDACIs] with activity against pancreatic cancer
cells and plasmodium falciparum. J. Med. Chem. 2008, in press.
(7) (a) Xin, Z.; Liu, G.; Pei,Z.; Szczepankiewicz, B. G.; Serby, M. D.;
Zhao,H. Preparation of arylisoxazolecarboxylates as protein-tyrosine
phosphatase (PTP1B) inhibitors. (Abbott Laboratories, USA) U.S. Pat.
Appl. Publ., 2004. (b) Zhao, H.; Liu, G.; Xin, Z.; Serby, M. D.; Pei,
Z.; Szczepankiewicz; B. G.; Hajduk, P. J.; Abad-Zapatero, C.;
Hutchins, C. W.; Lubben, T. H.; Ballaron, S. J.; Haasch, D. L.;
Kaszubska, W.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R.
Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B)
inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 5543–5546.
(8) Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.;
Njar, V. C. A new simple and high-yield synthesis of suberoylanilide
hydroxamic acid and its inhibitory effect alone or in combination with
retinoids on proliferation of human prostate cancer cells. J. Med. Chem.
2005, 48, 5047–5051.
References
(1) (a) Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform
selectivity in histone deacetylase inhibitors. Curr. Pharm. Des. 2008,
14, 505–528. (b) Bolden, J. E.; Peart, M. J.; Johnstone, R. W.
Anticancer activities of histone deacetylase inhibitors. Nat. ReV. Drug
DiscoVery 2006, 5, 769–784, and references cited therein. (c) Paris,
M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone Deacetylase
Inhibitors: From Bench to Clinic. J. Med. Chem. 2008, 51, 1505–
1528.
(2) (a) Grunstein, M. Histone acetylation in chromatin structure and
transcription. Nature 1997, 389, 349–352. (b) Wolffe, A. P.; Guschin,
D. Review: Chromatin structural features and targets that regulate
transcription. J. Struct. Biol. 2000, 129, 102–122. (c) Kurdistani, S. K.;
Grunstein, M.; Grunstein, M. Histone acetylation and deacetylation
in yeast. Nat. ReV. Mol. Cell Biol. 2003, 4, 276–284. (d) Struhl, K.;
Moqtaderi, Z. The TAFs in the HAT. Cell 1998, 94, 1–4.
(3) Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase
inhibitors: inducers of differentiation or apoptosis of transformed cells.
J. Natl. Cancer Inst. 2000, 92, 1210–1216.
(9) Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov,
N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins,
L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.;
Sehested, M. Determination of the class and isoform selectivity of
small molecule HDAC inhibotors. Biochem. J. 2008, 409, 581–589.
(10) (a) Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S. HDAC6, at the
crossroads between cytoskeleton and cell signaling by acetylation and
ubiquitination. Oncogene 2007, 26, 5468–5476. (b) Dompierre, J. P.;
Godin, J. D.; Charrin, B. C.; Cordelia´eres, F. P.; King, S. J.; Humbert,
S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the
transport deficit in Huntington’s disease by increasing tubulin acety-
lation. J. Neurosci. 2007, 27, 3571–3583.
(11) Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.;
Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.;
Maglathin, R. L.; McLean, T. H.; Bochkarev, A.; Plotnikov, A. N.;
Vedadi, M.; Arrowsmith, C. H. Human HDAC7 harbors a class IIa
HDAC-specific zinc binding motif and cryptic deacetylase activity.
J. Biol. Chem. 2008, Feb 19 (Epub ahead of print) PMID: 18285338.
(12) Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer. Lancet
2004, 363, 1049–1053.
(4) (a) Kelly, W. K.; Zhu, A. X.; Scher, H.; Curley, T.; Fallon, M.; Slovin,
S.; Schwartz, L.; Larson, S.; Tong, W.; Hartley-Asp, B.; Pellizzoni,
C.; Rocchetti, M. Dose escalation study of intravenous estramustine
phosphate in combination with Paclitaxel and Carboplatin in patients
with advanced prostate cancer. Clin. Cancer Res. 2003, 9, 2098. (b)
Carducci, M. A.; Gilbert, J.; Bowling, M. K.; Noe, D.; Eisenberger,
M. A.; Sinibaldi, V.; Zabelina, Y.; Chen, T. L.; Grochow, L. B.;
Donehower, R. C. Phase I clinical and pharmacological evaluation of
sodium phenylbutyrate on an 120 h infusion schedule. Clin. Cancer
Res. 2001, 7, 3047–3055. (c) Sasakawa, Y.; Naoe, Y.; Inoue, T.;
Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228,
a novel histone deacetylase inhibitor, on human lymphoma U-937 cells
in vitro and in vivo. Biochem. Pharmacol. 2002, 64, 1079–1090.
(5) (a) Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone
deacetylase inhibitors. AdV. Cancer Res. 2004, 91, 137–168. (b) Marks,
P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K.
Histone deacetylases and cancer: causes and therapies. Nat. ReV.
Cancer 2001, 1, 194–202.
(6) (a) Kozikowski, A. P.; Chen, Y. F.; Gaysin, A. M.; Savoy, D. N.;
Billadeau, D. D.; Kim, K. H. Chemistry, Biology, and QSAR Studies
of Substituted Biaryl Hydroxamates and Mercaptoacetamides as
HDAC Inhibitors-Nanomolar-Potency Inhibitors of Pancreatic Cancer
Cell Growth. ChemMedChem 2008, 3, 487–501. (b) Kozikowski, A. P.;
Chen, Y. F.; Gaysin, A.; Chen, B.; D’Annibale, M. A.; Suto, C. M.;
Langley, B. C. Functional Differences in Epigenetic Modulators:
Superiority of Mercaptoacetamide-Based Histone Deacetylase Inhibi-
tors Relative to Hydroxamates in Cortical Neuron Neuroprotection
(13) Haller, D. G. New perspectives in the management of pancreas cancer.
Semin. Oncol. 2003, 30, 3–10.
(14) Morrison, B. E.; Majdzadeh, N.; Zhang, X.; Lyles, A.; Bassel-Duby,
R.; et al. Neuroprotection by histone deacetylase-related protein. Mol.
Cell. Biol. 2006, 26, 3550–3564.
JM8002894